DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

Molecular Imaging Homepage

Phase I trial demonstrates safe use of radiotracer produced in minutes Manufactured using a Ga-68 generator and a cold kit vial

Bracco Imaging acquires SurgVision Enables development of a real-time fluorescence image-guided surgery platform

Blue Earth Diagnostics inks Axumin deal with Seibersdorf Laboratories Manufacturing and distribution in certain European countries

Two new imaging agents may help physicians make better and quicker treatment decisions Could determine therapy response in 24 hours

Researchers develop targeted alpha therapy protocol for prostate cancer Determines most effective therapy with the least number of side effects

Eyeing theranostics, Sofie Biosciences completes acquisition of Zevacor Pharma Growth of FDG also influenced decision

Blue Earth Diagnostics partners with GE to manufacture Axumin PET agent in UK Agreements were made in other European countries

RefleXion Medical selects MedCrypt to secure its new radiotherapy technology Updated FDA guidelines put cybersecurity at forefront

PET imaging used for the first time to evaluate Zika virus in mouse model May aid in development of therapeutic agents

Philips introduces its CardioMD IV SPECT system at ASNC meeting Smaller footprint and lower cost of ownership

Transaxial 11C-sarcosine hybrid PET/CT
of the anterior right prostate gland

Courtesy of the University of Michigan

New PET tracer for prostate cancer shows benefits over current standard: study

by Lauren Dubinsky , Senior Reporter
A study recently published in The Journal of Nuclear Medicine may have found a better PET tracer for imaging prostate cancer.

Researchers at the University of Michigan compared the effectiveness of the current standard, 11C-choline, to Carbon-11 labeled sarcosine (11C-sarcosine).

Story Continues Below Advertisement

CT, MRI, NM, SPECT/CT, PET & PET/CT service, refurbished systems and parts

Accelerate your ROI with our Black Diamond Certified refurbished systems. One year warranty - ISO 13485 Certified - FDA registered - Over 65k parts in inventory DOTmed Certified



Dr. Morand Piert, professor of radiology at the university, explained that 11C-sarcosine was considered for prostate cancer imaging because metabolomic data indicated strongly elevated tissue levels in localized prostate cancer, and particularly in metastatic disease.

Preclinical experiments involving mice revealed that tumor-to-background ratios obtained from 11C-sarcosine PET were much higher than those obtained with 11C-choline. They then performed the first 11C-sarcosine PET/CT scan on a human with prostate cancer and found it can generate high-contrast images.

The researchers concluded that 11C-sarcosine is a viable PET tracer for imaging prostate cancer and has potential benefits over 11C-choline.

Aside from skin cancer, prostate cancer is the most prevalent cancer among men in the U.S. The American Cancer Society estimates that there will be about 161,360 new cases of prostate cancer in 2017.

Sarcosine plays a vital role in the aggressiveness and progression of the disease. It's an excellent imaging target because it enters cells through proton-coupled amino acid transporters (PAT), which are overexpressed in solid tumors.

11C-sarcosine could also be used for identifying and characterizing other types of cancer. According to the researchers, that's because it's the first tracer that can interrogate the activity of PATs.

In the brain, PATs are involved in the neuronal amino acid transport process and in the intestinal tract, certain PATs act as nutrients and drug transporters.

The researchers also noted that PAT function has been connected to the amino acid-sensing engine that drives the activation of an important target for anti-cancer drugs. They believe that elevated 11C-sarcosine may be potentially useful for monitoring cancer treatments, but more research is needed to confirm that.

"The tracer could be useful for malignancies with elevated PAT expression," said Piert. "However, since the PAT expression is unknown for most malignancies, we honestly don't know the answer to the question."

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED